COMPANY:

Nanostics

"Nanostics Inc...is thrilled to announce the publication of the research supporting the development of the ClarityDX Prostate test. This test combines an optimized machine learning platform with blood-based biomarkers for clinically significant prostate cancer and clinical biomarker data to generate the patient's risk score for clinically significant (defined as Grade Group 2 and above) prostate cancer."

"Nanostics Inc...is thrilled to announce today that men can now provide blood samples for its ClarityDX Prostate test at LifeLabs collection sites across British Columbia, Saskatchewan, and Ontario....ClarityDX Prostate is available in British Columbia, Saskatchewan, and Ontario as a laboratory-developed test from Nanostics Clinical Laboratory in Edmonton, Alberta. In these provinces, tests are ordered, analyzed, and reported to the prescribing healthcare provider by Nanostics."

"Nanostics Inc...signed an agreement with Quebec-based CDL Laboratories (CDL) to expand access to the ClarityDX Prostate to men and their healthcare providers."

"Nanostics Inc...announced today that it received an investment from the University of Alberta Innovation Fund (UAIF) to help propel adoption of Nanostics' ClarityDX Prostate test in North America....Funds raised through the UAIF will go towards expanding access to ClarityDX Prostate across North America and supporting the expansion of its product pipeline, including the development of ClarityDX Bladder, a minimally invasive bladder cancer diagnostic test."

"Nanostics Inc...announce a partnership with Cancer Care Alberta, Alberta Health Services (AHS) to leverage advanced data analytics from Connect Care and the Cancer Care Alberta Data Environment for Cancer Inquiries and Decisions (DECIDe). This agreement will streamline access to Connect Care’s powerful and consolidated 'one record, one patient, one health clinical information system' to help drive diagnostic and prognostic innovations in urological care in Alberta."

"Nanostics is thrilled to announce the availability of the ClarityDX Prostate test at its newly accredited clinical lab in Edmonton, Alberta. This innovative blood test marks a significant advancement in prostate cancer screening. It provides critical support to men, aged 40 to 75, and their physicians in making more informed decisions, with 3X the accuracy, about whether a biopsy is required following a high prostate-specific antigen (PSA) test result."

"Nanostics Inc...announced today that the College of Physicians and Surgeons of Alberta (CPSA) granted provisional accreditation to Nanostics Clinical Laboratory in Edmonton, Alberta, Canada."

"Nanostics Inc...is excited to announce today that it has received the CE-IVD Mark for its ClarityDX Prostate^® test. This regulatory milestone allows Nanostics to market and sell ClarityDX Prostate^® in Europe, as well as other countries that require the CE Mark for market access."